Final positive readout for primary and several secondary endpoints presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at...
Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the...
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer...
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026...
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
- Tome Clearing Treatment is Dermata's second once-weekly skincare product under its Tome brand -- Tome Clearing Treatment includes a...
Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an investigational adjunctive therapy designed to...
Co-Founder, CEO Sulagna Bhattacharya to join Keynote Panel on navigating the cell and gene therapy landscape and driving market successCo-Founder,...
Co-Founder, CEO Sulagna Bhattacharya to join Keynote Panel on navigating the cell and gene therapy landscape and driving market successCo-Founder,...
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. TME Pharma receives €150,000 for 6 months of...
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to...
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License...
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company...
Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape...
-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients--2L...
Stockholders approved the conversion of the preferred stock issued in the June 2026 acquisition of Azora Therapeutics Azora’s common stock...
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering...
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Key TakeawaysRideshare access expanded for clinical trial participants—Lyft, Uber Health, and Bolt provide direct access to ground transportation and cut...